Navigation Links
Medarex Announces 2009 First Quarter Financial Results
Date:4/30/2009

PRINCETON, N.J., April 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2009.

Medarex's net loss for the quarter ended March 31, 2009 was $48.6 million, or ($0.38) per share. For the same period in 2008, Medarex's net income of $103.3 million, or $0.81 per share, included a gain of $151.8 million, or $1.19 per share, from the sale of 2.5 million shares of Genmab A/S stock in February 2008. Medarex's net loss for the quarter ended March 31, 2009 included a non-cash charge of $4.9 million, or ($0.04) per share, for stock-based compensation recorded in accordance with FAS 123(R) and a non-cash equity in net loss of affiliate charge of $2.4 million, or ($0.02) per share, related to its share of the net loss of Celldex Therapeutics, Inc. Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for the first quarter of 2009 was $41.3 million, or ($0.32) per share.

Total revenues for the quarter ended March 31, 2009 were $10.8 million as compared to $12.0 million for the same period in 2008.

Research and development expenses for the quarter ended March 31, 2009 decreased by $2.2 million, from $49.3 million in 2008 to $47.1 million in 2009. General and administrative expenses decreased by $1.9 million for the quarter ended March 31, 2009, from $12.4 million in 2008 to $10.5 million in 2009.

Medarex ended the first quarter of 2009 with approximately $322.8 million in cash, cash equivalents and marketable securities. In addition, as of March 31, 2009, the fair market value of Medarex's equity interests in Genmab and Celldex Therapeutics were approximately $85.3 million and approximately $32.3 million, respectively.

"Our first quarter accomplishments and steady progress of key development progra
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 The report ... Management Market by Product Type & Provider ... Analysis (2014-2019)” defines and segments the market ... revenues. , Browse 152 market data ... and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing ... common stock, and warrants to purchase up to an ... price of $4.00 per share and $.01 per warrant.  ... $5.00, are exercisable immediately, and expire 5 years from ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... 25 Inverness Medical,Innovations, Inc. (Amex: IMA ... products for the consumer and professional markets, announced,today ... Global Healthcare,Unplugged Conference being held April 30 - ... Florida. Ron Zwanziger, Chief Executive Officer, will,attend. His ...
... 25 Abbott,s broad,portfolio of businesses and expanding ... product pipeline provides a,foundation for continued growth as ... Chief Executive Officer Miles D.,White told shareholders today ... an outstanding year for Abbott across all of ...
... -- China Yingxia,International, Inc. (OTC Bulletin Board: ... provider in the nutraceutical industry engaged in ... food,products, supplements, and personal care products in ... that it has formally completed the,acquisition of ...
Cached Biology Technology:Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 2Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 3Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 4China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... infectious question about eating at restaurants: How clean are ... found that even when they washed dishes in cooler-than-recommended ... levels accepted in the Food and Drug Administration's Food ... milk—can be safe havens for bacteria when dried onto ...
... What influence does the variation in estrogen level ... Using functional Magnetic Resonance Imaging, Jean-Claude Dreher, a ... 1), in collaboration with an American team from ... directed by Karen Berman, has identified, for the ...
... patients who received an new intravenous adult stem cell ... such as cardiac arrhythmias, and had significant improvements in ... received a placebo, according to six-month Phase I study ... in Intervention: i2Summit in New Orleans on March 25. ...
Cached Biology News:Manual dishwashing study digs up dirt on dish cleanliness 2Manual dishwashing study digs up dirt on dish cleanliness 3The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients 2